دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 4,800,000 تومان- قیمت ویژه : 2,400,000تومان
پکیج دسترسی ۳ ماهه به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 93 ﺭﻭﺯ
قیمت : 1,500,000 تومان- قیمت ویژه : 750,000تومان
Whole-genome sequencing in breast cancer: is it ready for clinical application?
Radiotherapy-free approach in inoperable locally advanced non-small-cell lung cancer: are we ready for this shift?
doi : 10.1016/S1470-2045(25)00485-1
Volume 26, Issue 11, November 2025, Pages 1396-1398
Overall survival assessment in cancer drug trials: a luxury or a necessity?
It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer
It takes two to tango: importance of oestrogen receptor and progesterone receptor in endometrial cancer – Authors' reply
Unadjusted external controls and endpoint selection in Chinese cancer drug trials
WHO calls for investment in cancer prevention and care within a wider NCD strategy
New system to allow artificial intelligence clinical trials to take place across all UK NHS Trusts
Launch of a financing programme for women's cancers in the Indo-Pacific region
British Columbia's proposed law to combat deceptive practices promoting vaping products
Abdominal shielding not recommended for diagnostic imaging with ionising radiation during pregnancy
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden
Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering
Measurable residual disease-guided interventions in patients with acute myeloid leukaemia undergoing allogeneic haematopoietic cell transplantation: best practice recommendations from the European Society for Blood and Marrow Transplantation Practice Harmonisation and Guidelines Committee
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 1: review of the current state of the art
Artificial Intelligence for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO), part 2: challenges, opportunities, and recommendations for clinical translation
